Stockreport

CorMedix: Delayed Approval, Low Cash, Good Prospects [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF Summary CorMedix's DefenCath, an FDA-approved antimicrobial catheter lock solution, significantly reduces catheter-related bloodstream infections, addressing a critic [Read more]